Mobile-health Network Solutions

Mobile-health Network Solutions(MNDR)股票分析

$0.983

+0.043 (+4.42%)收盘时

Loading chart…
最高
1.040
开盘
0.969
成交量加权均价
0.99
成交量
261.51K
市值
—
最低
0.940
成交额
258.24K
企业价值/息税折旧摊销前利润(TTM)
0.00

Mobile-health Network Solutions is an artificial intelligence (AI)-powered digital health platform, with operations across Southeast Asia and expanding into the United States. The Company provides telemedicine, AI-driven health tools, and virtual clinic infrastructure to empower patients and doctors worldwide. The Company's MaNaDr platform is a 360-degree healthcare ecosystem which connects users and service providers through the range of healthcare services and product offerings that can be accessed through the mobile application and website. The healthcare solutions offered on its MaNaDr platform primarily encompass: MaNaDr Mobile Application, MaNaPharma, MaNaShop/MaNaStore, and MaNaCare. It offers teleconsultation services over its MaNaDr mobile application, through online consultations provided by its in-house medical team and external doctors from its network of clinic service providers. MaNaPharma includes B2B sales to clinics and other healthcare service providers.

AI 分析 of Mobile-health Network Solutions (MNDR)

持有

Currently, Mobile-health Network Solutions (MNDR) is not a strong buy due to its significant year-to-date decline of 83.49% and a negative RSI of 48.774, indicating a lack of strong momentum. Although the stock surged 24% following an acquisition announcement, it remains a penny stock with a current price of 0.94, which is only 0.7% of its 52-week high of 32.52, suggesting substantial risk. The main risk is its negative net income of -665468 reported in Q2 2026, which raises concerns about its profitability and financial stability.

估值指标

Mobile-health Network Solutions(MNDR)当前预期市盈率为 0.00,5 年平均预期市盈率为 -13.23。

预期市盈率

合理
5 年均值 P/E
-13.23
当前P/E
0.00
高估
23.13
低估
-49.59

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-11.33
当前EV/EBITDA
0.00
高估
26.12
低估
-48.79

预期市销率

合理
5 年均值 P/S
3.36
当前P/S
0.00
高估
14.72
低估
-8.01

Alphio AI 对 MNDR 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%MNDR

$1.16

情景价格

基

基准

基准 · 50%MNDR

$1.10

情景价格

悲

悲观

悲观 · 25%MNDR

$0.87

情景价格

事件时间线

2026-06-26 (ET)

20:00:00

Mobile-Health Network Solutions Trading Halted, News Pending

2026-03-09 (ET)

06:20:00

Offering for Selling Shareholders

2025-07-16 (ET)

11:03:30

Mobile-health Network Solutions files $300M mixed securities shelf

2025-03-21 (ET)

17:18:54

Mobile-health Network Solutions files to sell 3.34M Class A ordinary shares

2024-12-17 (ET)

07:35:44

Mobile-health Network Solutions launches ManaSocial platform

资讯

MNDR 常见问题 —— 由 Alphio AI 解答

Mobile-health Network Solutions is an artificial intelligence (AI)-powered digital health platform, with operations across Southeast Asia and expanding into the United States. The Company provides telemedicine, AI-driven health tools, and virtual clinic infrastructure to empower patients and doctors worldwide. The Company's MaNaDr platform is a 360-degree healthcare ecosystem which connects users and service providers through the range of healthcare services and product offerings that can be accessed through the mobile application and website. The healthcare solutions offered on its MaNaDr platform primarily encompass: MaNaDr Mobile Application, MaNaPharma, MaNaShop/MaNaStore, and MaNaCare. It offers teleconsultation services over its MaNaDr mobile application, through online consultations provided by its in-house medical team and external doctors from its network of clinic service providers. MaNaPharma includes B2B sales to clinics and other healthcare service providers. It operates in the Technology sector (PREPACKAGED SOFTWARE industry).

Currently, Mobile-health Network Solutions (MNDR) is not a strong buy due to its significant year-to-date decline of 83.49% and a negative RSI of 48.774, indicating a lack of strong momentum. Although the stock surged 24% following an acquisition announcement, it remains a penny stock with a current price of 0.94, which is only 0.7% of its 52-week high of 32.52, suggesting substantial risk. The main risk is its negative net income of -665468 reported in Q2 2026, which raises concerns about its profitability and financial stability.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易